目的 观察吉西他滨联合顺铂方案治疗ER、PR、HER-2均阴性对蒽环类耐药的晚期转移性乳腺癌的疗效和安全性.方法 34例对蒽环或紫杉类耐药晚期转移性乳腺癌患者,经免疫组化证实ER、PR、HER-2均阴性,给予吉西他滨联合顺铂方案治疗,具体用药为:吉西他滨1000mg/m2静脉滴注,第1,8天;顺铂25mg/m2静脉滴注,第1～3天.21天为1周期,至少2个周期,2周期后评价疗效和毒副反应.结果 34例患者均可评价疗效,获完全缓解(CR)2例(5.9%),部分缓解(PR)12例(35.3%),稳定(SD)14例(41.2%),进展(PD)6例(17.6%),总有效率(CR+PR)为41.2%;中位疾病进展时间为5.2个月.主要不良反应包括骨髓抑制和胃肠道反应,无化疗相关死亡.结论 吉西他滨联合顺铂方案对蒽环类或紫杉类耐药的转移性三阴性乳腺癌有较好的近期疗效,不良反应可耐受,是有效的解救方案之一.%Objective To evaluate the efficacy and safety of combination chemotherapy of gemcitabine and cisplatin for anthracycine-resistant triple-negative metastatic breast cancer patients.Methods Thirty-four patients with immunohistochemical proved triple-negative metastatic breast cancer were given gemeitabine 1000mg/m2,d1 ,d8 and DDP 25mg/m2 ,d1-d3.Treatments were repeated every 21 days and all patients received at least two cycles.Results Two cases (5.9％) had complete response (CR), 12 cases (35.3％ ) had partial response(PR) ,while 14 cases(41.2％ ) had stable disease(SD) and 6 cases(20.6％ ) got progressive disease (PD); the overall response rate was 41.2％.The median time to progression (TIP) was 5.2 months, no patients died in correlated with the gemcitabine combined with eisplatin regimen.Myelosuppression and gastrointestinal tract reaction were the most common toxicities.Conclusion Cemeitabine combined with eisplatin regimen is well effective for patients with anthracyeline-resistant triple-negative metastatic breast cancer.Drug-related toxicities are tolerable.This regimen can be considered as a salvage regimen for those patients.
展开▼
